US pivotal trial is a multi-center study evaluating a bioabsorbable hemodialysis vascular access implant across complex hemodialysis patients representing real-world practice > 50% of target enrollment reached across 20 sites in the United States EINDHOVEN, The Netherlands – 2 July, 2026 – Xeltis, a leading developer of transformative implants that enable the natural creation […]
Brings extensive experience in design, development, and implementation of US medtech clinical trial strategy for hemodialysis and vascular access Follows expansion of Xeltis’ clinical presence in the US after recent IDE approval for aXessTM US pivotal trial EINDHOVEN, The Netherlands, 23 July 2024 – Xeltis, a leading developer of transformative implants that enable the natural […]
aXess is a restorative arteriovenous dialysis conduit which allows vascular access for hemodialysis through the creation of a new, permanent, living vessel EINDHOVEN, The Netherlands, 13 June 2024 – Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces that it has gained approval from the US […]
